|
| |
Intercell is listed on the Vienna Stock
Exchange
Munich/Zug, 10 March 2005 – Global Life Science Ventures (GLSV) today
announced that Intercell AG
successfully listed on the Vienna Stock Exchange on February 28. Intercell
shares started trading on the Prime Market of the
Vienna Stock Exchange (Wiener Börse)
under the symbol ICLL. On the first day of trading, the stock
closed at EUR 5.70 which
represented a 3.64% increase over the offer price of EUR 5.50 per share. The
public listing allowed
Intercell to raise EUR 46.75 million in a transaction that was oversubscribed.
GLSV was the lead investor
in the series C financing round of Intercell which was the last financing
round before the IPO. The series C financing took place in 2003. GLSV holds an
ongoing position on the
Board of Directors of Intercell.
Dr Hans Küpper,
Partner at GLSV, remarked: “Intercell has made outstanding progress as a
growing biotechnology company with a clear, original
focus on developing preventative and
therapeutic vaccines for the treatment of infectious
diseases.” He added: “In just over 6 years,
it has made the transition from a promising start-up company
to a publicly listed enterprise
with a broad pipeline of vaccine candidates addressing
significant burdens of disease. It has
been both exciting and rewarding to follow the company’s
development. Through the public
listing, Intercell is well on track to establish itself as a leading European
biotechnology
company with considerable staying power and commercial
potential.”
Founded in 1998,
Intercell discovers and develops innovative immunological products and
technologies. Intercell is engaged in the development
of so-called "smart vaccines" that are
based on the combination of proprietary antigens and
immunizers (adjuvants). The company’s
technology has been endorsed by collaborative agreements with
global pharmaceutical
companies including Aventis and Merck&Co, Inc..
Intercell has a
broad development pipeline with a vaccine for Japanese Encephalitis entering
phase III trials, a vaccine for Hepatitis C undergoing
phase II trials, and five products focused
on infectious diseases in the pre-clinical phase, including a
Pneumonia vaccine, a Group A
Streptococcus vaccine and a traveler's diarrhea vaccine.
Dr. Peter
Reinisch, Partner at Global Life Science Ventures, commented: “Intercell is the
second company financed by GLSV’s second fund, GLSV
II, to exit within the last six
months.”
About Global
Life Science Ventures:
GLSV is a leading, independent venture capital fund focusing exclusively on
the life sciences. With
offices in Germany and Switzerland, GLSV is dedicated to providing finance
primarily to early-stage
groups, originating from universities, scientific institutions or industry, as
well as selected later stage
companies, including buy-outs. The group currently advises and
manages funds greater than €200 million. Up to now,
GLSV has financed 27 leading
biotechnology companies, nine of which have completed a
successful exit through IPO or
M&A. GLSV has built a broadly diversified portfolio of
companies in pharmaceuticals,
diagnostics, medical devices, and biotechnology.
Global Life
Science Ventures
Industry-born team – Proven track record – Global perspective
Germany Switzerland
GLSV GmbH GLSV AG
Von-der-Tann-Str. 3 Postplatz 1, P.O. 626
D – 80539 München CH – 6301 Zug
Tel. +49 (0)89 288 151 0 Tel. +41 (0)41 727 19 40
Fax +49 (0)89 288 151 30 Fax +41 (0)41 727 19 45
www.glsv-vc.com
mailbox@glsv-vc.com
For additional information, please contact:
Rochat & Partners
Christophe Lamps
Tel. +41 22 718 37 46
Fax +41 22 786 54 58
E-mail: clamps@rochat-pr.ch
| |
|
